Intra-cellular Therapies share price today
(NASDAQ: ITCI)

Name: Intra-cellular Therapies Share Price Today (NASDAQ: ITCI) - Intra-cellular Therapies Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Intra-cellular Therapies share price is $127.07 & ₹10,990.28 as on 24 Jan 2025, 2.30 'hrs' IST

$127.07

▲

-0.08

(-0.06%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Intra-cellular Therapies share price in Dollar and Rupees. Guide to invest in Intra-cellular Therapies stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Intra-cellular Therapies, along with analyst recommendations, forecasts, and comprehensive financials.

Intra-cellular Therapies share price movements

Today's Low: $127.07
Today's High: $127.42
$127.07
0.0%
Downside
Day's Volatility :0.27%
Upside
0.27%
52 Weeks Low: $62.78
52 Weeks High: $128.00
$127.07
50.59%
Downside
52 Weeks Volatility :50.95%
Upside
0.73%

Intra-cellular Therapies Returns

Period	Intra-cellular Therapies, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	67.72%	-5.5%	0.0%
6 Months	58.17%	-4.3%	0.0%
1 Year	89.83%	1.6%	0.0%
3 Years	172.62%	9.8%	-11.0%

Intra-cellular Therapies Key Statistics

in dollars & INR

Previous Close	$127.15
Open	$127.19
Today's High	$127.42
Today's Low	$127.07
Market Capitalization	$13.4B
Today's Volume	$6.2M
52 Week High	$128.0
52 Week Low	$62.78
Revenue TTM	$613.7M
EBITDA	$-121.1M
Earnings Per Share (EPS)	$-0.87
Profit Margin	-14.07%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-9.9%

How to invest in Intra-cellular Therapies Stock (ITCI) from India?

It is very easy for Indian residents to invest directly in Intra-cellular Therapies from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Intra-cellular Therapies stock in both Indian Rupees (INR) and US Dollars (USD). Search for Intra-cellular Therapies or ITCI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Intra-cellular Therapies or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Intra-cellular Therapies shares which would translate to 0.007 fractional shares of Intra-cellular Therapies as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Intra-cellular Therapies, in just a few clicks!

Returns in Intra-cellular Therapies for Indian investors in Rupees

Investment Value

₹1,00,000

Intra-cellular Therapies investment value today

Current value as on today

₹1,93,768

Returns

₹93,768

(+93.77%)

Returns from Intra-cellular Therapies Stock

₹89,713 (+89.71%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Intra-cellular Therapies

2133.33%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Investment in Intra-cellular Therapies from India has grown in the last 30 days as on Jan 24, 2025. 2133.33% more purchase transactions for Intra-cellular Therapies in the last 30 days versus the previous period.

158%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Intra-cellular Therapies on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 158% more investors are searching Intra-cellular Therapies in the last 30 days versus the previous period.

Global Institutional Holdings in Intra-cellular Therapies

FMR Inc
10.49%
Vanguard Group Inc
9.08%
BlackRock Inc
5.87%
JPMorgan Chase & Co
4.99%
Wasatch Advisors LP
3.63%
venBio Select Advisor LLC
2.88%

Analyst Recommendation on Intra-cellular Therapies

Buy

86%Buy

13%Hold

0%Sell

Based on 23 Wall street analysts offering stock ratings for Intra-cellular Therapies(by analysts ranked 0 to 5 stars)

Based on 23 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Intra-cellular Therapies

What analysts predicted

Downside of 2.77%

Target:

$123.55

Current:

$127.07

Insights on Intra-cellular Therapies

Price Movement
In the last 1 month, ITCI stock has moved up by 51.4%
Increasing Revenue
Revenue is up for the last 19 quarters, 882.51K → 175.15M (in $), with an average increase of 22.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -15.24M → -26.32M (in $), with an average decrease of 34.3% per quarter

Intra-cellular Therapies Technicals Summary

Sell

Neutral

Buy

Intra-cellular Therapies is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Intra-cellular Therapies Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Intra-cellular Therapies, Inc.	49.17%	58.17%	89.83%	172.62%	447.12%
Haleon Plc Spon Ads	-5.34%	-0.11%	14.11%	24.43%	24.43%
Zoetis Inc.	0.67%	-7.35%	-11.05%	-14.66%	22.56%
Neurocrine Biosciences Inc.	5.56%	-0.03%	4.08%	93.28%	48.77%
Viatris Inc.	-11.31%	-7.78%	-5.11%	-24.11%	-31.82%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.7	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	28.0	28.0	1.65	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	31.32	31.32	2.61	5.88	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	39.03	39.03	0.34	6.6	0.16	0.12	NA	26.87
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Intra-cellular Therapies, Inc.	Buy	$13.4B	447.12%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$41.8B	24.43%	28.0	10.75%
Zoetis Inc.	Buy	$75.2B	22.56%	31.32	26.55%
Neurocrine Biosciences Inc.	Buy	$14.9B	48.77%	39.03	17.21%
Viatris Inc.	Hold	$13.5B	-31.82%	224.4	-5.87%

Intra-cellular Therapies Dividend announcements

Intra-cellular Therapies Earnings
Intra-cellular Therapies’s price-to-earnings ratio stands at None
Read More

About Intra-cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Organization	Intra-cellular Therapies
Employees	610
CEO	Dr. Sharon Mates Ph.D.
Industry	Health Technology

Management People of Intra-cellular Therapies

Name	Title
Dr. Sharon Mates Ph.D.	Co-Founder, Chairman & CEO
Mr. Michael I. Halstead J.D.	President
Dr. Suresh K. Durgam M.D.	Executive VP & Chief Medical Officer
Mr. Mark Neumann	EVP & Chief Commercial Officer
Mr. Sanjeev Narula	Executive VP & CFO
Dr. Robert E. Davis Ph.D.	Senior VP & Chief Scientific Officer
Mr. Juan Fernando Sanchez M.D.	Vice President of Corporate Communications & Investor Relations
Ms. Karen Patruno Sheehy Esq.	Senior VP & Chief Compliance Officer
John P. Condon	Senior Vice President, General Counsel & Secretary
Dr. Michael Olchaskey	Senior VP & Head of Regulatory Affairs

Important FAQs about investing in Intra-cellular Therapies (ITCI) from India :

What is Intra-cellular Therapies share price today?

Intra-cellular Therapies share price today stands at $127.07, Open: $127.19 ; Previous Close: $127.15 ; High: $127.42 ; Low: $127.07 ; 52 Week High: $128.00 ; 52 Week Low: $62.78. The stock opens at $127.19, after a previous close of $127.15. The stock reached a daily high of $127.42 and a low of $127.07, with a 52-week high of $128.00 and a 52-week low of $62.78.

Can Indians buy Intra-cellular Therapies shares?

Yes, Indians can invest in the Intra-cellular Therapies (ITCI) from India.

With INDmoney, you can buy Intra-cellular Therapies at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Intra-cellular Therapies at zero transaction cost.

How can I buy Intra-cellular Therapies shares from India?

It is very easy to buy Intra-cellular Therapies from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Intra-cellular Therapies be purchased?

Yes, you can buy fractional shares of Intra-cellular Therapies with INDmoney app.

What are the documents required to start investing in Intra-cellular Therapies stocks?

To start investing in Intra-cellular Therapies, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.